Overview

Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder

Status:
RECRUITING
Trial end date:
2028-06-11
Target enrollment:
Participant gender:
Summary
To learn about the safety and effects of low-dose sirolimus in participants with RUNX1-FPD.
Phase:
PHASE2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Treatments:
Sirolimus